Institutional members access full text with Ovid®

Share this article on:

The Impact of Childhood Meningococcal Serogroup C Conjugate Vaccine Programs in Canada

Bettinger, Julie A. PhD, MPH*; Scheifele, David W. MD*; Le Saux, Nicole MD; Halperin, Scott A. MD; Vaudry, Wendy MD§; Tsang, Raymond PhDthe members of the Canadian Immunization Monitoring Program, Active (IMPACT)

The Pediatric Infectious Disease Journal: March 2009 - Volume 28 - Issue 3 - p 220-224
doi: 10.1097/INF.0b013e31819040e7
Original Studies

Background: Conjugate meningococcal vaccines may decrease the incidence of disease. The staggered implementation of universal childhood meningococcal C conjugate (MenC) immunization programs across Canada offers an opportunity to evaluate the influence of these programs.

Methods: From 2002 to 2006, we conducted active, population-based surveillance for adult and pediatric hospital admissions related to meningococcal infections at the 12 centers of the Canadian Immunization Monitoring Program, Active (IMPACT), in collaboration with local public health officials.

Results: A total of 376 cases were reported during the 5 years of surveillance. Yearly totals were as follows: 96 in 2002, 73 in 2003, 81 in 2004, 58 in 2005, and 68 in 2006. Case fatality was 9.3% and adults had a significantly higher case fatality rate than children.

Average incidence per 100,000 was 0.62 (95% confidence interval [CI]: 0.50–0.76) in 2002 and 0.42 (95% CI: 0.32–0.53) in 2006. The highest rates were in children age 0 to 4 years, followed by adolescents age 15 to 19 years. Incidence of group C disease decreased significantly during the 5 years from 0.23 (95% CI: 0.16–0.32) in 2002 to 0.08 (95% CI: 0.04–0.14) in 2006, whereas incidence remained stable for groups B, Y, and W135. The decrease in group C disease was seen in provinces that first implemented MenC immunization programs.

Conclusions: A substantial decrease in group C incidence occurred in provinces with early MenC immunization programs. Serogroup C incidence remained stable in provinces without MenC programs. We found no evidence of serogroup replacement.

From the *Vaccine Evaluation Center, BC Children's Hospital and the University of British Columbia, Vancouver, British Columbia, Canada; †Children's Hospital of Eastern Ontario and the University of Ottawa, Ottawa, Ontario, Canada; ‡Canadian Center for Vaccinology, IWK Health Center and Dalhousie University, Halifax, Nova Scotia, Canada; §Stollery Children's Hospital and University of Alberta, Edmonton, Alberta, Canada; and ¶National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.

Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text; simply type the URL address into any Web browser to access this content. Clickable links to the material are provided in the HTML text and PDF of this article on the Journal’s Web site (www.pidj.com).

Accepted for publication October 6, 2008.

Supported by a grant from Sanofi-Pasteur. The Canadian Immunization Monitoring Program, Active (IMPACT), is a national surveillance initiative managed by the Canadian Pediatric Society and conducted by the IMPACT network of pediatric investigators.

Address for correspondence: Julie Bettinger, PhD, MPH, BC Children's Hospital, L427-4500 Oak St, Vancouver, BC V6H 3N1, Canada. E-mail: jbettinger@cw.bc.ca.

© 2009 Lippincott Williams & Wilkins, Inc.